Accordingly to this classification, our observations enabled us to subdivide our cohort in 4 ‘immune-inflamed’ RMS, displaying expression of PDL1 in immune cells surrounding and within the tumor burden, which may likely respond to anti-PD-L1/PD-1 therapy, and 5 ‘immune-excluded’ RMS with PD-L1 staining present in immune cells that do not penetrate the parenchyma of the tumor but rather are retained in the surrounding stroma, which are expected to rarely respond to PD-L1/PD-1 agents [25]. This evidence concerns the gene CD274 and neoplasm.